1.A Case of Methimazole-Induced Cholestatic Jaundice with Steroid Therapy.
Wan Sup KIM ; Jae Han KIM ; Byung Ok YOON ; Young Min KIM ; Sang Hun SONG ; Myoung Jin OH ; Heon Gyen HWANG ; Chul Hee KIM ; Dong Won BYUN ; Kyo Il SUH ; Myung Hi YOO
Journal of Korean Society of Endocrinology 1999;14(3):592-598
Cholestatic jaundice caused by imidazole derivatives is a rare complication of antithyroid drug therapy. We present a case of cholestatic jaundice with systemic hypersensitivity reaction, which developed in a 27-year old male one day after exposure to methimazole. The patient showed clinical improvement and gradual resolution of jaundice after the discontinuation of methimazole and treatment with prednisolone. Histologic findings of liver revealed bile pigment, predominantly in centrilobular area, and infiltration of chronic inflammatory cells in a few portal area without evidence of degeneration or necrosis of hepatocytes. Methimazole could be presumed as etiologic agent from clear chronological relationship and the lack of other causative factors. We report this unusual case with review of literature.
Adult
;
Bile Pigments
;
Drug Therapy
;
Hepatocytes
;
Humans
;
Hypersensitivity
;
Jaundice
;
Jaundice, Obstructive*
;
Liver
;
Male
;
Methimazole
;
Necrosis
;
Prednisolone
2.Clinical study on effect of tuihuan decoction rectoclysis in hyperbilirubinemia of newborn.
Xiu-fang DUAN ; Hong BAO ; Zhao-zhu GONG
Chinese Journal of Integrated Traditional and Western Medicine 2005;25(6):508-510
OBJECTIVETo study the therapeutic effect and feasibility of rectoclysis with Tuihuang decoction (RTD) in treating hyperbilirubinemia of newborns.
METHODSOne hundred and seventy-five newborns with hyperbilirubinemia were randomly divided into the treated group and the control group. They were treated with western medicine plus double faced blue treatment while the treated group were given RTD additionally. Blood bilirubin was detected by micro-bilirubin detector daily during the treatment course. The time of jaundice regression, the speed of blood bilirubin reducing, liver function, and condition of rebounding were observed.
RESULTSThe 7-day curative rate of jaundice in the treated group was superior to that in the control group, showing significant difference (P < 0.05). The average speed of blood bilirubin reducing daily in the treated group was quicker than that in the control group (P < 0.01). The improvement of liver function, such as AST, ALT and gamma-GT in the treated group was superior to that in the control group (P < 0.01). Rebound rate of blood bilirubin in the control group was significantly higher than that in the treated group (P < 0.05).
CONCLUSIONRTD is an ideal therapy for treatment of hyperbilirubinemia of newborn, it shows obvious clinical efficacy and can effectively prevent the rebound of blood bilirubin.
Administration, Rectal ; Drugs, Chinese Herbal ; administration & dosage ; Female ; Humans ; Hyperbilirubinemia ; drug therapy ; Infant, Newborn ; Jaundice, Neonatal ; drug therapy ; Male ; Phytotherapy
3.Chemotherapy and Low Dose Interleukin-2 Therapy for Acute Myeloid Leukemia in Patient with Down Syndrome.
Jong Tai KIM ; Ki Soo PAI ; Moon Kyu KIM ; Jo Won JUNG ; Dong Moon SOH
Korean Journal of Pediatric Hematology-Oncology 2001;8(1):126-131
A 4-day-old patient with Down syndrome (DS) visited out patient department (OPD) because of jaundice and VSD. Peripheral blood smear showed 21% of myeloblast. After 4 weeks of observation, WBC count was 55,100/mm3 (blast 90%). BM aspirate showed AML (M7) and treatment was started with low dose Ara-C (20 mg/m2 for 21 days). After remission, maintenance therapy was done with low dose Ara-C (16 mg/m2 for 21 days), 6-TG (40 mg/m2 for 21 days) and low dose IL-2 (0.5 106U/m2 for 21 days) alternatively for 2 years. The patient remained in complete remission and VSD was corrected at 9 months of age. This case shows that remission can be achieved with low dose Ara-C and it can be maintained thereafter with low dose Ara-C, 6-TG and IL-2. Low dose IL-2 has the advantage of selectively activating immune cells with high affinity receptors, low treatment related morbidity, good compliance which can be injected at OPD. As the patients with DS have defect in IL-2 secretion, IL-2 may have an beneficial effects on treating AML in DS.
Compliance
;
Cytarabine
;
Down Syndrome*
;
Drug Therapy*
;
Granulocyte Precursor Cells
;
Humans
;
Interleukin-2*
;
Jaundice
;
Leukemia, Myeloid, Acute*
4.Therapeutic mechanisms of single Chinese medicine herb or their extracts for extrahepatic obstructive jaundice.
Xi-ping ZHANG ; Feng-mei QIU ; Xia WANG
Chinese journal of integrative medicine 2014;20(6):474-480
Obstructive jaundice (OJ) is classified as extrahepatic OJ or intrahepatic OJ. Extrahepatic OJ is attributed to a variety of intricate etiological factors. Research has begun with Chinese medicine (CM), which can be used as an adjunctive therapy for extrahepatic OJ. Particular attention has been paid to the therapeutic effects and their mechanisms of single CM herb and relevant extracts. The roles of single CM or their extracts during adjunctive therapy for extrahepatic OJ have been described briefly. This review focuses on the effects and their mechanisms of relevant herbal medicines.
Animals
;
Drugs, Chinese Herbal
;
therapeutic use
;
Humans
;
Jaundice, Obstructive
;
drug therapy
;
Plant Extracts
;
therapeutic use
5.Multiple Myeloma Manifestated by Necrotizing Fasciitis.
Jae Sung PARK ; Yong Keun CHO ; Myeong Sin MA ; Jae Yong KWAK ; Chang Yeol IM
Korean Journal of Hematology 2000;35(3-4):284-286
Multiple myeloma manifestated by necrotizing fasciitis is quite rare. Most of the patients affected with necrotizing fasciitis have some risk factors : Chronic general or local diseases, leukoenia, immunodeficiency diseases, malignancy, and an age of 50 years or more. We have experienced a case of necrotizing fasciitis associated with multiple myeloma presented as jaundice, pain, swelling of right buttock, ab-domiminal distension in 65-year-old man. His general status was improved after incision and drainage of wound and systemic chemotherapy. We recommend that multiple myeloma should be considered if necrotizing fasciitis is diagnosed.
Aged
;
Buttocks
;
Drainage
;
Drug Therapy
;
Fasciitis, Necrotizing*
;
Humans
;
Jaundice
;
Multiple Myeloma*
;
Risk Factors
;
Wounds and Injuries
6.Systematic review and Meta-analysis of effect of Yinzhihuang Oral Liquid in treatment of neonatal jaundice.
Cai-Die TIAN ; Jian LYU ; Yan-Ming XIE ; Meng-Hua SUN
China Journal of Chinese Materia Medica 2019;44(24):5303-5312
To systematically review effectiveness and safety of Yinzhihuang Oral Liquid in the treatment of neonatal jaundice. A systematic retrieval was performed throughout China National Knowledge Infrastructure( CNKI),Wan Fang,VIP,Sino Med and PubMed,Medline,Cochrane Library databases from the establishment to April 2019. Randomized controlled trials of Yinzhihuang Oral Liquid in treatment of neonatal hyperbilirubinemia were retrieved. Clinical studies in line with the inclusion criteria were involved for data extraction,and the quality of the included literatures was evaluated by the risk bias assessment tool in the Cochrane review manual. Finally,Meta-analysis was performed by Rev Man 5.3 software. A total of 30 studies were involved,involving 3 923 child patients,including1 940 in observation group and 1 983 in control group. According to the results of Meta-analysis,the total effective rate( RR = 1. 22,95%CI[1. 18,1. 26],P<0. 000 01),level of TBi L after treatment( MD =-38. 78,95%CI[-48. 38,-29. 18],P<0. 000 01),time to jaundice resolution( MD =-1. 76,95% CI[-2. 10,-1. 41],P < 0. 000 01) and daily average decrease value of bilirubin( MD =11. 67,95%CI[8. 89,14. 45],P<0. 000 01) of observation group were significantly better than those of control group,with statistically significant differences. Adverse reactions were reported in nine studies,mainly including diarrhea,vomiting,fever,rash and other symptoms,which did not affect the treatment effect. The effectiveness of Yinzhihuang Oral Liquid combined with conventional therapy in treating neonatal jaundice was better than conventional therapy alone,with little adverse reactions. However,most of literatures included had a low research quality,which impacted the reliability of the conclusion. Therefore,it is suggested to conduct more largesample-size,multicenter,scientifically designed,strictly implemented high-quality randomized controlled trials in the future,in order to study the efficacy and safety of Yinzhihuang Oral Liquid in the treatment of neonatal jaundice.
China
;
Drugs, Chinese Herbal/therapeutic use*
;
Humans
;
Infant, Newborn
;
Jaundice, Neonatal/drug therapy*
;
Reproducibility of Results
7.Obstructive Jaundice in Patients with Gastric Cancer.
Keun Won RYU ; Young Jae MOK ; Seung Joo KIM ; Chong Suk KIM ; Bum Hwan GOO
Journal of the Korean Surgical Society 2000;58(6):812-815
PURPOSE: Although obstructive jaundice is a rare presentation, it is an ominous sign of poor prognosis in patients with gastric cancer. Thus, we investigated the incidence, the clinical features, the pathologic characteristics, the treatment modality, and the prognosis for obstructive jaundice in patients with gastric cancer. METHODS: A retrospective analysis was done for patients with gastric cancer who had presented with obstructive jaundice at Korea University Guro Hospital from January 1988 to December 1998. RESULTS: During that period, 2546 patients were diagnosed with gastric cancer, and obstructive jaundice was revealed in 20 (0.78%). The mean age was 58 13 years, and the sex ratio (male:female) was 5.7:1. Jaundice was the first presentation in two patients, and it developed in the other 18 patients during the follow-up period after the initial operation or chemotherapy. The level of total bilirubin was 16.7 8.1 mg/dl, and the cause of the jaundice was lymph-node enlargement at the porta hepatis. A percutaneous transhepatic biliary drainage (PTBD) was done in 17 patients, and improvement was seen in 13 (76%). The most common site of the obstruction was common hepatic duct (CHD) (60%). Antrally located, moderately differentiated and Borrmann type-III gastric cancers were commonly associated with obstructive jaundice. The mean duration from jaundice to death was 4.6 6.2 month. CONCLUSION: Obstructive jaundice is very rare in patients with gastric cancer and is associated with poor survival. Although the bilirubin level was decreased by a PTBD, the survival was not improved. An extended lymphadenectomy along the hepatoduodenal ligament is necessary to prevent obstructive jaundice due to recurrence particularly, in patients with antrally located, moderately differentiated and Borrmann type-III carcinomas.
Bilirubin
;
Drainage
;
Drug Therapy
;
Follow-Up Studies
;
Hepatic Duct, Common
;
Humans
;
Incidence
;
Jaundice
;
Jaundice, Obstructive*
;
Korea
;
Ligaments
;
Lymph Node Excision
;
Prognosis
;
Recurrence
;
Retrospective Studies
;
Sex Ratio
;
Stomach Neoplasms*
8.Role of Radiation Therapy for Locally Advanced gastric Carcinoma Management.
Sei Chul YOON ; Yoon Kyeoung OHO ; Kyeong Sub SHINN ; Yong Whee BAHK ; In Chul KIM ; Kyung Sik LEE
Journal of the Korean Society for Therapeutic Radiology 1988;6(1):41-48
Thirty-five patients with locally advanced gastric carcinoma were treated with combined modalities of external radiation therapy (RT) and 5-FU based chemotherapy at the Division of Radiation Therapy, Department of Radiology, Kangnam St, Mary's Hospital, Catholic University Medical College from May 1983 to May 1987. The purpose of this retrospective study is for the evaluation of the palliative response to RT. There were 25 men and 10 women. The age ranged from 38 to 80 years (median: 56 years). The pathologic classification showed 14 (40%) poorly differentiated, 12(34%) moderately differentiated, 3 (9%) well differentiated adenocarcinomas, 2 mucinous cystadenocarcinomas, 1 signet ring cell and 3 not specified ones. The time intervals from the initial surgicopathologic diagnosis to the starting day of RT was within 1 year for 18 (51%), 1 to 2 years for 8 (23%) and 2 to 3 years for 5 (14%), respectively. The major symptoms to be treated were pain in 30 (86%), mass for 29 (83%), obstruction for 11 (31%) and jaundice for 9 (26%) patients. The response rate (patient number of positive response/total patient number) according to treated radiation doses were observed as follows; 14/16(88%) for 40~50 gy, 8/10 (80%) for over 50 gy, 6/8 (75%) for 30~40 gy and 8/15 (53%) for 20~30 gy in decreasing order. The over all survival was 3.6 months and that of 5FU+RT, FAM+RT and RT alone groups were 4.6 months, 3.7 months and 2.5 months respectively. Complications induced by RT were nausea and vomiting in 16 (46%), diarrhea in 7 (20%), leukopenia in 6 (17%) and anemia and intercurrent pneumonia in each 3 (9%) patients in decreasing order.
Adenocarcinoma
;
Anemia
;
Classification
;
Cystadenocarcinoma, Mucinous
;
Diagnosis
;
Diarrhea
;
Drug Therapy
;
Female
;
Fluorouracil
;
Humans
;
Jaundice
;
Leukopenia
;
Male
;
Nausea
;
Pneumonia
;
Retrospective Studies
;
Vomiting
9.The Palliative Radiation Therapy in Malignant Extra-Hepatic Biliary Obstruction.
Chul Seung KAY ; Hong Suk JANG ; Sung Hwan KIM ; Mi Ryeong RYU ; Yeon Shil KIM ; Su Mi CHUNG ; Sei Chul YOON
The Journal of the Korean Society for Therapeutic Radiology and Oncology 1999;17(3):209-216
PURPOSE: To evaluate the effectiveness of external radiation therapy and the prognostic factors, we retrospectively analyzed therapeutic results of malignant extrahepatic biliary obstruction (EHBO). METHODS AND MATERIALS: We analyzed the results of the external radiation therapy in 59 patients of inoperable malignant EHBO who had been treated with more than 10 Gy of external radiation therapy from April 1984 to December 1996. There were 21 stomach cancer (35.6%), 12 pancreas cancer (20.3%), 15 extrahepatic biliary cancer (18.6%) and 11 another cancer (18.6%). Their pathologies were confirmed in 31 patients (52.5%). They divided into 27 adenocarcinoma and 4 nonadenocarcinoma. Their chief complaints were jaundice in 47 patients (79.7%) and abdominal pain in 15 patients (49.2%). Twelve patients had slightly increased bilirubin level in liver function test without jaundice. We treated twenty four patients (40.6%) with percutaneous transhepatic biliary drainage (PTBD) and 32 patients (54%) with systemic chemotherapy (CT). We performed external radiation therapy (ERT) upto 10.8~55.8 Gy (median 37.8 Gy) with palliative aim. RESULTS: Overall median survival duration was 7.80+/-1.15 months. The response rates of jaundice were 81.8% in PTBD group and 66.7% in non-PTBD group without statistical significance. The improving rate of jaundice was not significantly different in decreased ratio of total bilirubin level. But abdominal pain was more decreased in CT group than non-CT group (P<0.05). The significant prognostic factors were high performance status (Karnofski Performance Status >70), total radiation dose more than 35 Gy and good response of pain after therapy. There were increased in bacterial cholagitis in PTBD group and gastrointestinal complications in CT group. CONCLUSION: External radiotheapy could improve jaundice and abdominal pain in malignant EHBO patients. Overall survival duration was prolonged in patients with higher performance status and patients who had been treated with more than 35 Gy of total radiation dose. In the future, we expect not only better palliative role but also the prolongation of survival of using the ERT combined with other treatment method. But to achieve certain conclusion, we need futher study consisted with many kinds of treatment methods including new technologies in RT.
Abdominal Pain
;
Adenocarcinoma
;
Bilirubin
;
Drainage
;
Drug Therapy
;
Humans
;
Jaundice
;
Liver Function Tests
;
Pancreatic Neoplasms
;
Pathology
;
Radiotherapy
;
Retrospective Studies
;
Stomach Neoplasms
10.Preoperative biliary drainage for pancreatic cancer
Gastrointestinal Intervention 2018;7(2):67-73
Pancreatic cancer is a leading cause of cancer-related morbidity and mortality, but any meaningful improvement in its prognosis remains elusive. The lack of early diagnostic methods means that many patients only present when symptoms develop, such as obstructive jaundice. Once a diagnosis of pancreatic cancer has been made in a patient with obstructive jaundice, then a decision should be made if the patient is a candidate for surgical resection. Patients who are candidates for surgical resection generally do not need preoperative biliary drainage, unless they present with cholangitis, or if they require neo-adjuvant chemotherapy. If preoperative biliary drainage is to be done, then patient factors and local expertise should guide appropriate interventions. The evidence for endoscopic retrograde cholangiopancreatography as a first-line therapy for biliary decompression is strong; However, the use of percutaneous transhepatic biliary drainage as well as endoscopic ultrasound-guided biliary drainage has generally not been found to be inferior. Finally, to ensure ongoing patency and minimize complications, an appropriate self-expanding metal stent should ideally be placed.
Cholangiopancreatography, Endoscopic Retrograde
;
Cholangitis
;
Decompression
;
Diagnosis
;
Drainage
;
Drug Therapy
;
Endoscopy
;
Humans
;
Jaundice, Obstructive
;
Mortality
;
Pancreatic Neoplasms
;
Prognosis
;
Stents
;
Ultrasonography